Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    20212250 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Terminated
Has Results
A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY 43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)
Condition: Carcinoma, Non-Small Cell Lung
Interventions: Drug: Nexavar (Sorafenib, BAY43-9006) + carboplatin + paclitaxel;   Drug: Carboplatin plus Paclitaxel

Indicates status has not been verified in more than two years